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Summary
Telomeres are protected by capping structures consisting of
core protein complexes that bind with sequence specificity
to telomeric DNA (reviewed in [1]). In their absence, telo-
meres trigger a DNA damage response, materialized in
accumulation at the telomere of damage response proteins,
e.g., phosphorylated histone H2AX (gH2AX), into telomere-
dysfunction-induced foci [2, 3]. Telomere uncapping occurs
transiently in every cell cycle in G2 [4], following DNA repli-
cation, but little is known about how protective structures
are reassembled or whether this process is controlled by
the cell-cycle surveillance machinery. Here, we report that
telomere capping is monitored at the G2/M transition by
the p53/p21 damage response pathway. Unlike their wild-
type counterparts, human and mouse cells lacking p53
or p21 progress into mitosis prematurely with persisting
uncapped telomeres. Furthermore, artificially uncapped
telomeres delay mitotic entry in a p53- and p21-dependent
manner. Uncapped telomeres that persist in mitotic p53-
deficient cells are shorter than average and religate to
generate end-to-end fusions. These results suggest that a
p53-dependent pathway monitors telomere capping after
DNA replication and delays G2/M progression in the pres-
ence of unprotected telomeres. This mechanism maintains
a cell-cycle stage conducive for capping reactions and
prevents progression into stages during which uncapped
telomeres are prone to deleterious end fusions.
Results and Discussion
DNA Damage Response Factors at Human Telomeres
during Mitosis
Telomere uncapping leads to checkpoint activation and
recruitment of DNA damage response factors to the telomere
(e.g., 53BP1, MDC1, gH2AX, and ATM), visualized as micro-
scopically defined telomere-dysfunction-induced foci (TIFs,
reviewed in [5]). Telomeres become transiently uncapped in
every cell cycle following their replication in S phase, and the
ensuing ATM-dependent response is thought to promote
the reassembly of protective telomeric structures in G2 [4].
To monitor telomere recapping at the G2/M transition under*Correspondence: madalena.tarsounas@rob.ox.ac.uk
3Present address: Epigenetics and Cancer Biology Program (PEBC),
Catalan Institute of Oncology (ICO), Gran Via s/n, 08907 L’Hospitalet de
Llobregat, Barcelona, Spainphysiological conditions, we synchronized human HeLa
1.2.11 cells by double thymidine block and release. gH2AX
foci were detectable in G2, and a subset of these localized to
telomeres, indicative of TIFs (see Figure S1A, available online).
Upon entry into mitosis, several sites of gH2AX labeling per-
sisted, and these preferentially colocalized with telomeres
labeled with an anti-TRF2 antibody (Figure 1A). The frequency
of these mitotic TIFs was comparable to that of interphase TIFs
(Figures S1A), suggestive of persistence of G2-uncapped
telomeres into mitosis. To confirm gH2AX localization at telo-
meres, we visualized TIFs on mitotic chromosomes by coloc-
alization of gH2AX and telomeric fluorescent in situ hybridiza-
tion (FISH) signals (Figures 1B and 1C). In addition to gH2AX,
we also detected MDC1 at mitotic telomeres (Figure S1B), a
damage response mediator at the G2/M transition [6]. In con-
trast, 53BP1, another damage response protein [7], was not
detected at mitotic telomeres. HeLa 1.2.11 cells carry rela-
tively long telomeres (w17 kb [8]). We therefore also analyzed
HeLa OHIO cells with shorter telomeres (w3.4 kb [8]) and
again observed gH2AX labeling of mitotic telomeres (Figures
1B and 1C). The number of gH2AX-labeled telomeres in mitotic
HeLa OHIO cells was even higher than in HeLa 1.2.11 cells
(Figure 1D).
gH2AX staining at deprotected telomeres can extend over
approximately 570 kb into the subtelomeric region in human
cells [9]. Consistently, the chromatin domain covered by
gH2AX often extended beyond the telomeric FISH signal or
the region of TRF2 staining in our experiments (Figures 1A–
1C). To address whether the gH2AX signal indeed originated
from telomeric DNA, we analyzed gH2AX binding to telomere
DNA by using chromatin immunoprecipitation (ChIP; Fig-
ure 2A). We used HeLa 1.2.11 cells either untreated or arrested
in mitosis by addition of colcemid. An antibody against gH2AX
efficiently pulled down telomeric DNA from mitotic cells,
whereas less enrichment was observed in unsynchronized
cells. An antibody against the telomere-associated protein
TRF2 was used as a positive control that precipitated telo-
meric DNA with similar yield in both cases. Preimmune serum
served as a control for nonspecific binding, and no precipita-
tion was observed when a nontelomeric rDNA probe was
used instead of a telomere probe for detection. These results
confirm specific association of gH2AX with telomeres, which
can clearly be seen in cells arrested in mitosis.
Mitotic TIFs Mark Short, Uncapped Telomeres
We next addressed whether a correlation existed between
telomere length and the occurrence of mitotic TIFs. Our initial
results suggested that HeLa OHIO cells with shorter telomeres
show a somewhat higher incidence of telomeric gH2AX stain-
ing during mitosis compared to HeLa 1.2.11 cells (Figure 1D).
This observation was confirmed in mitotic chromosome prep-
arations of HeLa 1.2.11 cells, where we observed that nuclei
with stronger telomeric FISH signals, indicative of long telo-
meres (Figure 2B, long), typically lack TIFs. In contrast, TIFs
were abundant in metaphases with shorter telomeres, on the
basis of the FISH signal intensity (Figure 2B, short). To quanti-
tatively assess whether gH2AX labeling was linked to short
telomere length, we measured the intensities of individual
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Figure 1. gH2AX Persists at Telomeres during Mitosis
(A) HeLa 1.2.11 cells were arrested in mitosis with colcemid treatment and
mitotic chromosomes spread onto glass slides. Preparations were stained
with anti-TRF2 (green) and anti-gH2AX antibodies (red). DNA was counter-
stained with DAPI (blue).
(B) Mitotic chromosomes isolated from HeLa 1.2.11 and HeLa OHIO cells
arrested in mitosis with colcemid were spread onto glass slides via the
cytospin method. Preparations were fixed and stained with anti-gH2AX
monoclonal antibody (green). Telomeres were visualized with a Cy3-conju-
gated (CCCTAA)6-PNA probe (red). Yellow arrows indicate TIFs. White
arrows point at gH2AX foci that do not colocalize with telomeres.
(C) Enlarged images, including the areas marked with yellow rectangles in (B).
(D) Quantification of TIFs in HeLa 1.2.11 and HeLa OHIO cells. One hundred
metaphases were scored for each cell line. Error bars represent standard
deviation (SD) of three independent experiments.
This figure is related to Figures S1 and S2.
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522telomeric FISH signals in mitotic HeLa 1.2.11 cells by using the
Q-FISH technique and recorded their gH2AX status in the
same preparation. This revealed that shorter telomeres wereindeed more likely to be labeled by gH2AX. Twenty percent
of gH2AX-positive telomeres, but only 7% of all telomeres,
were shorter than 10 kb in length (Figure 2B).
To determine whether mitotic gH2AX labeling is indicative of
uncapped telomeres, we artificially created telomere uncap-
ping by overexpression of dominant-negative TRF2 lacking
both Myb and N-terminal basic domain (TRF2DMDB [10]) in
human T4 cells under control of a doxycyclin-repressible pro-
moter. TRF2DMDB levels increased over 7 days after removal of
doxycyclin from the growth medium (Figure 2C). Before induc-
tion, only a few TIFs were detected on spread metaphase
chromosomes, similar to what we observed in HeLa cells. In
contrast, 7 days after induction of TRF2DMDB, the majority of
mitotic telomeres were labeled by gH2AX (Figure 2C). We
conclude that uncapped telomeres display mitotic gH2AX
staining. TIFs persisting into mitosis in cells with intact telo-
mere structure may therefore reflect telomeres that have
remained uncapped after their replication in S phase.
The p53/p21 Pathway Prevents Mitotic Entry
with Uncapped Telomeres and Telomere Fusion
Telomere capping after DNA replication is thought to be
completed during the G2 phase of the cell cycle [4]; therefore,
the widespread presence of mitotic TIFs in a range of human
cell lines came as a surprise. However, the cells so far used
in our studies lacked functional p53. To investigate whether
p53 plays a role in preventing mitotic uncapped telomeres,
we first analyzed the human U2OS cell line that is proficient
for p53 function [11]. gH2AX labeling on mitotic chromosomes
was rarely seen but increased to frequencies similar to HeLa
cells after siRNA-mediated depletion of p53 or p21 from these
cells (Figure S2). To confirm the dependence of mitotic TIFs on
the p53 status, we analyzed isogenic mouse embryonic fibro-
blasts (MEFs) carrying wild-type p53 or a targeted deletion in
the p53 gene [12]. gH2AX labeling of mitotic chromosomes
was again rarely seen in wild-type MEFs but occurred fre-
quently in p532/2 MEFs (Figure 3A). As was the case in human
HeLa cells, Q-FISH analysis revealed that gH2AX staining was
preferentially observed at short telomeres of p532/2 MEFs
(data not shown). These results suggest that p53 is required
either for efficient capping of telomeres in G2 before the time
of mitotic entry or to prevent progression into mitosis while
telomere capping reactions are ongoing. p53 has been shown
to delay mitotic entry in response to DNA damage by upregu-
lation of its downstream target p21 [13]. We observed mitotic
TIFs in MEFs carrying a p21 deletion [14] as frequently as in
MEFs lacking p53 (Figure 3A). This suggests that one role of
p53 is to delay cell-cycle progression into mitosis by p21
induction when uncapped telomeres persist. Association of
gH2AX with sites close to the telomeres of mitotic chromo-
somes has been reported in late generation Terc2/2 T cells
[15]. When we quantified mitotic TIFs in Terc2/2 shp53 MEFs
[16] with short telomeres (G4;w20.88 kb average), we found a
substantial increase compared to wild-type MEFs (w36.4 kb
average) (Figures 3A and 3B). This confirms our observation
that shorter telomeres are more prone to persisting in an
uncapped state.
To obtain insight into the fate of uncapped telomeres in the
absence of p53, we examined the frequency of chromosome
abnormalities in p532/2 MEFs (Figure 3C). As expected, we
observed an increased incidence of DNA breaks and complex
structural aberrations in p532/2 MEFs, as compared to p53+/+
MEFs established from three embryos derived for each
genotype (data not shown). In addition, we observed an
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Figure 2. gH2AX Associates Preferentially with
Short, Uncapped Telomeres
(A) HeLa 1.2.11 cells were arrested in mitosis with
colcemid or remained untreated. ChIP analyses
were carried out as described in the Experimental
Procedures. Error bars represent SD of three
independent experiments.
(B) HeLa 1.2.11 cells were arrested in mitosis
with colcemid, and mitotic chromosomes were
spread onto glass slides via the cytospin method.
Preparations were stained with anti-gH2AX anti-
bodies (green) and a Cy3-conjugated (CCCTAA)6-
PNA probe (red). DNA was counterstained with
DAPI (blue). For Q-FISH analysis of telomere
length distribution, n = 4814 telomeres were
analyzed, of which 315 stained positive for
gH2AX.
(C) Control cells (T4 + Dox) or cells expressing
the human TRF2DMDB variant (T4 – Dox) were
arrested in mitosis with colcemid, and mitotic
chromosomes were spread onto glass slides.
Preparations were stained with anti-gH2AX anti-
bodies (green) and a Cy3-conjugated (CCCTAA)6-
PNA probe (red). TRF2DMDB expression was
confirmed by western blotting. Recombinant
full-length human TRF2-His6, migrating more
slowly because of its epitope tag, served as a
specificity control. Tubulin was used as a loading
control.
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523increase in chromosome and chromatid fusions in p532/2
MEFs. Importantly, we observed a significant 4.4-fold increase
in the frequency of chromosome and chromatid fusions that
displayed telomeric DNA at the fusion site (Figure 3C). End-
to-end fusions containing telomeric sequences are a charac-
teristic signature of telomeric dysfunction [10]. These fusions
may break in subsequent mitoses, thus starting a bridge-
fusion-breakage cycle [17] that may contribute to the overall
genomic instability of p53-deficient cells. Our results demon-
strate that p53 is required to protect telomeres from end-to-
end fusions.
To address whether p53 affects the telomere capping reac-
tion, we synchronized cells from a pair of isogenic human colo-
rectal cancer cell lines, proficient or deleted for p53 (HCT116
p53+/+ or p532/2) [13], by double thymidine block and release.
We monitored the occurrence of TIFs at the G2/M transition,
7–11 hr after the second release. At 7 hr, both p53+/+ and
p532/2 cells had completed DNA replication and stained posi-
tive for the G2 specific marker CENP-F [18] (Figure S3). Most
cells in both populations exhibited more than two TIFs at this
time. By the time cells entered mitosis, as seen by the increasein phosphohistone H3 staining, TIFs
were no longer observed in p53+/+ cells.
In contrast, TIFs remained detectable in
most p532/2 cells throughout mitosis
and as cells re-entered G1, at 10 hr
after release. This suggests that p53 is
required for efficient completion of telo-
mere capping and that the p53 response
pathway may have an impact on the
capping reaction. Alternatively, homolo-
gous recombination reactions that are
part of telomere capping may become
disfavored as p532/2 cells enter mitosis
prematurely [19, 20]. As reportedpreviously [13] and as shown here by staining with phospho-
histone H3 (Figure S3), a marker for the G2/M transition, mitotic
entry of p532/2 cells was somewhat advanced compared to
p53+/+ cells.
Uncapped Telomeres Trigger ATM- and
p53/p21-Dependent G2/M Arrest
To directly address the ability of p53 to delay the G2/M transi-
tion in the presence of uncapped telomeres, we disrupted telo-
mere protective structures by depleting components of the
telomeric complex in mouse and human cells and compared
mitotic indexes between p53+/+ and p532/2 cells. p53+/+ and
p532/2 primary MEFs carrying homozygous floxed TRF1
alleles (TRF1F/F) [21] were infected with retroviruses encoding
Cre recombinase or vector control. Deletion of TRF1, as moni-
tored by western blotting, resulted in marked telomere uncap-
ping visualized by gH2AX-labeled telomeres (Figure 4A). TIF
quantification in interphase cells revealed no impact of p53
status on TIF frequency (data not shown). To analyze mitotic
entry of these cells after telomere uncapping, we determined
the fraction of cells in mitosis at the indicated times after
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-/- Figure 3. p53 and p21 Prevent Progression into
Mitosis in the Presence of Uncapped Telomeres
in MEFs
(A) MEFs established from wild-type, p532/2,
p212/2, or Terc2/2 p53sh embryos were arrested
in mitosis with colcemid, and mitotic chromo-
somes were spread via the cytospin method.
Preparations were fixed and stained with
anti-gH2AX monoclonal antibody (green). Telo-
meres were visualized with a Cy3-conjugated
(CCCTAA)6-PNA probe (red). DNA was counter-
stained with DAPI (blue). Insets show enlarged
images of the areas marked with yellow
rectangles.
(B) TIF frequency was determined by counting
the number of foci in 100–150 metaphases.
Error bars represent SD of three independent
experiments.
(C) Metaphase chromosomes from p53+/+ and
p532/2 MEFs were stained with DAPI and telo-
meres were visualized by FISH. Examples of
end-to-end fusions with telomeric sequences at
the fusion site and DNA breaks are shown.
(D) End-to-end fusions with or without telomeric
repeats at the fusion site were quantified in at
least 142 metaphases from each genotype. Error
bars represent SD of values obtained for three
different embryos of each genotype. The p value
was calculated with an unpaired two-tailed t test.
*p < 0.05.
This figure is related to Figure S3.
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524infection (Figure 4B). p53+/+ cells displayed a very low mitotic
index after uncapping, compared to TRF1-positive control
cells. p532/2 cells showed a higher mitotic index in the TRF1-
proficient background compared to p53+/+ cells, and this was
not affected after loss of telomere protection by TRF1 deletion.
FACS analysis of DNA content (Figure 4B) confirmed that
the low mitotic index in p532/2 cells with uncapped telomeres
was due to an arrest of cells in G2/M rather than G1/S.
Similarly, p53 was required to prevent mitotic entry of human
cells with uncapped telomeres (Figure S4A). When TRF2 was
depleted with siRNA in p53+/+ or p532/2 HCT116 cells, the
ability of cells to enter mitosis was significantly impaired only
in the presence of functional p53. Additionally, human cells
depleted of p21 and TRF2 entered mitosis at a higher rate
compared to p21-proficient cells (Figure S4B). This suggests
that a p53-dependent pathway recognizes uncapped telo-
meres and delays mitotic entry via activation of p21. Consis-
tent with this idea, we observed p21 induction after siRNA-
mediated depletion of TRF2 (Figure S4B).
TIF formation at uncapped telomeres during S phase is ATM
dependent [2]. Similarly, we found that mitotic TIFs were
strongly reduced when we treated HeLa 1.2.11 cells with the
ATM inhibitor Ku55933 (Figure S4C). In comparison, MO59J
cells deficient in DNA-PK activity [22] showed similar levels
of mitotic TIFs to those of HeLa and MO59K control cells.
Instead, Ku55933 addition prevented mitotic TIF formation in
MO59J and MO59K cells to the same degree as in HeLa cells.
This demonstrates that gH2AX labeling of mitotic telomeres
depends on ATM, but not DNA-PK, characteristic for the
response to uncapped telomeres.
To gain mechanistic insight into the control of p53 activa-
tion at the G2/M transition, we monitored in synchronized
human cells ATM-dependent p53 phosphorylation at Ser15,
an event known to occur in response to DNA damage [23,
24]. Ser15 phosphorylation occurred in S phase and also at
the G2/M transition monitored by FACS analyses of DNAcontent and phospho-H3 staining (Figure 4C). Concomitant
activation of p21 was observed only in G2/M, emphasizing
its importance at this stage of the cell cycle. Another target
of p53, 14-3-3s [25], showed a similar induction pattern to
that of p21, raising the possibility that 14-3-3s is also involved
in the response to telomere damage. To test this hypothesis,
we synchronized U2OS cells that have been depleted of TRF2
by using siRNA (Figure 4D). Although increased ATM-depen-
dent Ser15 p53 phosphorylation, as well as p21 induction,
occurred specifically in response to TRF2 depletion, 14-3-3s
expression was not significantly augmented. This suggests
that p21, and to a lesser degree 14-3-3s, act downstream
of p53 in response to telomere dysfunction at the G2/M
transition.
Traditionally, much research on p53 has focused on its role
in regulating cell-cycle arrest at the G1/S transition in response
to DNA damage and other types of cellular stress. An ATM-
and p53-dependent checkpoint that detects altered telomeric
state at the G1/S transition was proposed to act as a regula-
tor of the cellular response to telomere dysfunction [26]. How-
ever, several reports also support a role for the p53 pathway at
the G2/M transition (reviewed in [25, 27]). Here we provide
evidence that telomere uncapping during normal cell-cycle
progression triggers a p53-dependent checkpoint at the
G2/M transition. The nature of the signal could be the linear
telomere structure transiently generated during DNA replica-
tion in S phase, which resembles an unrepaired DSB. It has
been proposed that telomeres in a linear form trigger a DNA
damage response to initiate the reactions required for elonga-
tion, processing, and capping [4], and reactions related
to those of DNA repair by homologous recombination are
required to form a protective t loop structure [20]. Our results
suggest that ATM, as a sensor of linear telomeres, at least in
part uses p53 as an effector to delay mitotic entry and halt
the cell cycle in a state conducive for the capping processes
to be completed. The physiologic p53 response to uncapped
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Figure 4. p53 Controls the G2/M Transition in Response to Uncapped Telo-
meres and Undergoes ATM-Dependent Phosphorylation
(A) Western blot detection of mouse TRF1 in primary p53+/+TRF1F/F and
p532/2TRF1F/F MEFs of the indicated genotypes treated with empty pBabe
vector (ve) or Cre recombinase (Cre) 3 days after selection. Recombinant
human TRF1-His6 served as a specificity control. Tubulin was used as
loading control. p532/2TRF1F/F MEFs were arrested in mitosis with colce-
mid and then mitotic chromosomes were spread via the cytospin method
and stained with anti-gH2AX monoclonal antibody (green). Telomeres
were visualized with a Cy3-conjugated (CCCTAA)6-PNA probe (red). DNA
was counterstained with DAPI (blue). Yellow arrows indicate TIFs.
(B) The mitotic index was determined in n = 350–500 cells for each genotype,
treatment, and time point. FACS analysis of DNA content was performed on
propidium iodide-stained cells. Error bars represent SD of two independent
experiments. p values were calculated with an unpaired two-tailed t test.
**p < 0.01 and ***p < 0.001.
(C) U2OS cells were synchronized at the G1/S transition via a double thymi-
dine block. Extracts prepared from cells at the indicated times after release
were immunoblotted as indicated.
(D) U2OS cells transfected with control GFP or TRF2 siRNAs were grown for
24 hr before synchronization by double thymidine block and release.
Extracts prepared at the indicated times after release were immunoblotted
as shown.
This figure is related to Figure S4.
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525telomeres, which naturally occur in every round of cell division
after DNA replication, extends our understanding of this
important tumor suppressor.Experimental Procedures
Cell Culture and Treatments
Human T4 [10], HeLa 1.2.11, HeLa OHIO, U2OS, HCT116 wild-type and
p532/2 cells [13], and MO59J and MO59K [22] (all obtained from Cancer
Research UK Cell Services) were cultivated in monolayers in Dulbecco’s
modified Eagle’s medium (DMEM) (Invitrogen) supplemented with antibi-
otics (penicillin and streptomycin, Sigma Aldrich) and 10% fetal bovine
serum (FBS, Invitrogen). Primary MEFs were isolated from day 13.5 embryos
embryos as previously described [28] and cultivated in DMEM medium
(Invitrogen) supplemented with antibiotics (penicillin and streptomycin,
Sigma Aldrich) and 10% FBS (Invitrogen). p212/2 MEFs [14] were a gift
from M. Serrano (CNIO). Isogenic wild-type and p532/2 MEFs, isogenic
TRF1F/F p532/2 and TRF1F/F p53+/+, and MEFs established from C57BL6
embryos of 4th generation (G4) Terc2/2 immortalized by p53 depletion
(shp53 [29]) have been previously described [12, 16, 21]. ATM inhibitor
Ku-55933 ([30]; a gift from G. Smith) was added at 10 mM final concentration
for 1 hr prior to collection. Mitotic cell arrest was carried out by addition of
0.1 mg/ml colcemid (GIBCO) to human cells and 0.2–0.3 mg/ml to MEF
cultures, followed by 4–12 hr incubation at 37C. The synchronization of
HeLa 1.2.11, HCT116, and U2OS cells was performed with a double thymi-
dine block. In brief, exponentially growing cells were arrested by addition of
thymidine (2 mM) to the growth media for 16 hr, followed by two washes in
HBSS and release into fresh media for 10 hr. Cells were then arrested
a second time by addition of thymidine (2 mM) and 16 hr incubation, then
washed as above and released into fresh media.
Antibodies
The following antibodies were used for immunoblotting: rabbit polyclonal
antisera raised against human TRF2 [31], mouse TRF2 (2390 [32]), human
histone H3 (a gift from A. Verreault), Ser15-p53 (Cell Signaling), and human
p21 (C-19, Santa Cruz); and mouse monoclonal antibodies raised against
phosphorylated ATM-Ser1981 (Cell Signaling), mouse TRF1 (TRF-78,
Abcam), p53 (DO-1, Santa Cruz Biotechnology), 14-3-3s (Upstate), and
a-tubulin [31] (Cancer Research UK Monoclonal Antibody Service). Addi-
tional antibodies used for imunoflourescence detection were mouse mono-
clonal antibodies raised against MDC1 (Abcam) and phosphorylated
histone H2AX-Ser 139 (Upstate) and a rabbit polyclonal antiserum raised
against 53BP1 (Novus) and CENP-F (Abcam). Antibodies used in ChIP anal-
yses were rabbit polyclonal antibodies anti-phosphorylated histone H2AX-
Ser 139 (Upstate) and anti-human TRF2.
Preparation of Metaphase Spreads
Mitotic cells were collected by mitotic shake off and swollen in hypotonic
buffer (10 mM Tris-HCl, pH 7.5, 10 mM NaCl, 5 mM MgCl2) at 37
C for
5 min. For IF-FISH, cells were either spun onto coverslips via a cytospin
centrifuge (Cytospin 4, Fisher) or spread across a slide presoaked in 2%
paraformaldehyde as described [33] and dried. For Q-FISH, cells were fixed
in a freshly prepared 3:1 mix of methanol:glacial acetic acid. Nuclear prep-
arations were dropped onto slides presoaked in 45% acetic acid and left to
dry overnight.
Immunofluorescence and FISH
Metaphase spreads prepared as above were fixed in 4% paraformaldehyde
with 0.1%–0.5% Triton X-100 in PBS, permeabilized with 0.5% Triton X-100
in PBS, and subjected to immunofluorescence staining as described [31]. In
brief, metaphase spreads were incubated in antibody dilution buffer (1%
goat serum, 0.3% BSA, 0.005% Triton X-100 in PBS) for 10 min, then in
primary antibody overnight. After three washes in antibody dilution buffer
supplemented with 0.005% Triton X-100, secondary antibody was added
for 1 hr. All antibody incubations were at room temperature. Samples
were then washed and fixed again in 4% paraformaldehyde in PBS. After
three washes in PBS, slides were briefly dried at room temperature. FISH
was performed as described [31] with 15 mg/ml Cy3-conjugated
[CCCTAA]6-PNA telomeric probe (Applied Biosystems). Chromosomes
were visualized with DAPI.
Q-FISH, Mitotic Index, and Chromosome Analyses
Primary MEFs were isolated from day 13.5 embryos from p532/2 [12] and
p212/2 mice [14] as described [34], passaged once and treated with
0.1 mg/ml colcemid for 4 hr, trypsinized, and fixed as above for metaphase
spreads. Q-FISH analyses and statistical analyses of chromosomal aberra-
tions and telomere length were carried out as described [28, 31]. Fifty
anaphases per cell line from two independent cell samples of each
Current Biology Vol 20 No 6
526genotype were scored. One fusion event was defined as the result of the
joining of two or more chromosomes. The end-to-end fusion index was
calculated as the number of events per total number of metaphases.
For determining the mitotic index, dried metaphase spreads were mounted
in DAPI and visualized by fluorescence microscopy. Nuclei with condensed,
evenly stained chromosomes were counted as mitotic. Between 350 and
500 nuclei were scored for each time point.Supplemental Information
Supplemental Information includes four figures and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.cub.2010.01.046.
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